Contract Pharma Manufacturing News

  1. Agios Enters Exclusive Global License Agreement With Oscotec To Develop And Commercialize Next-Generation SYK Inhibitor Cevidoplenib 6/1/2026

    Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced an agreement with Oscotec, a clinical-stage drug discovery and development company focused on immunology and oncology, headquartered in South Korea, to license the exclusive global rights to cevidoplenib, a novel, next-generation, oral spleen tyrosine kinase (SYK) inhibitor.

  2. Intravacc And Primrose Bio Renew Partnership To Enhance Conjugate Vaccine Development 6/1/2026

    Intravacc, a leading global contract development and manufacturing organization (CDMO) specializing in infectious disease and therapeutic vaccines and biologics, and Primrose Bio, a biotechnology company with leading technologies that improve the manufacturing of next-generation therapeutics, renew their strategic partnership to enhance the development and supply of conjugate vaccines.

  3. Camurus Announces Expansion Of Lilly Collaboration 6/1/2026

    Camurus today announced that Eli Lilly and Company (“Lilly”) has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025.

  4. CEPI Fast-Tracks Three Bundibugyo Ebolavirus Vaccine Candidates 6/1/2026

    The Coalition for Epidemic Preparedness Innovations (CEPI) will urgently accelerate development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda.

  5. Hanmi Signs Licensing Deal With Lilly For sonefpeglutide (LAPSGLP-2 analog) 6/1/2026

    Hanmi Pharm. Co., Ltd. (“Hanmi”) today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi’s biologic drug candidate sonefpeglutide (LAPSGLP-2 analog) with Eli Lilly and Company (“Lilly”).

  6. Andelyn Biosciences Establishes The Andelyn Foundation To Support Families Living With Rare And Ultra-Rare Diseases 5/29/2026

    Andelyn Biosciences Inc., a patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced the unveiling of The Andelyn Foundation, a nonprofit organization dedicated to supporting families living with rare and ultra-rare diseases through awareness, fundraising, and compassionate community engagement.

  7. Andelyn Biosciences Launches LVV Curator® Platform, Bringing Proven Viral Vector Platform Pedigree To Lentiviral Vector Manufacturing For Cell Therapies 5/29/2026

    Andelyn Biosciences, a leading cell and gene therapy contract development and manufacturing organization (CDMO), today announced the launch of its LVV Curator® Platform, a standardized lentiviral vector (LVV) manufacturing solution built on the same proven modular approach that supports clinical and commercial adeno-associated virus (AAV) programs.

  8. Andelyn Biosciences Receives Dark Horse Consulting Certification Of Gene Therapy Manufacturing Systems And Capabilities Within Its Initiative For Certification Of Manufacturing Capabilities (ICMC™) Program 5/29/2026

    Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced it has received full certification under the Initiative for Certification of Manufacturing Capabilities (ICMC) program from Dark Horse Consulting, recognizing the company’s capability to support advanced therapies manufacturing with its quality and production systems.

  9. Quotient Sciences Advances AI-Designed Drug Product Into Clinical Development 5/29/2026
  10. Ratio Therapeutics And PharmaLogic Expand Manufacturing Collaboration To Support Clinical Development Of [Ac-225]RTX-2358 5/29/2026

    Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced an expanded manufacturing collaboration with PharmaLogic Holdings Corp. (PharmaLogic), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, to support the continued clinical development and future commercialization readiness of Ratio's lead therapeutic candidate, [Ac-225]RTX-2358.